Drug Prices
About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a Centers for Disease Control and Prevention report released today.
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive Vice President Tom Nickels said during a panel discussion today at America’s Health Insurance Plans’ National Health Policy Conference in…
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market to lower prices.
The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy solutions.
Eight in 10 U.S. adults say prescription drug costs are “unreasonable,” and one in four say their prescription medicines are difficult to afford, according to the latest Kaiser Family Foundation Health Tracking Poll.
Patients and their providers rely on these prescription drugs for treating injury and managing illness. Yet the drug companies and their shareholders have been treating America’s patients and providers like a piggybank.
The Senate Finance Committee today held the second in a planned series of bipartisan hearings on high prescription drug prices, which featured executives from drug companies AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Committee Chairman Richard Neal, D-Mass., and Ranking Member Kevin Brady, R-Texas, said they are committed to working on bipartisan reforms to lower drug prices.